

## Investment Strategy

The investment objective of the Sub-Fund is to achieve medium to long-term returns through investment primarily in growth and innovation oriented Indian stocks which are already listed or soon to be listed on a Recognised Exchange.

Lower Risk Potentially lower rewards Higher Risk Potentially higher rewards



## Performance Analysis

NAV (Mo-End)	11.75	<i>There is insufficient data to produce a useful indication of past performance for the share class/fund.</i>
NAV 52 Wk High	12.07	
NAV 52 Wk Low	8.72	
# of Holdings	19	
Fund Size (USD mil)	25.58	

Source: Morningstar Direct & UTI IS

## Fund Information

Firm Name	UTI International (Singapore) Pvt. Ltd.
Advisor	UTI Asset Management Co Ltd
Domicile	Ireland
UCITS	Yes


Morningstar Rating Overall	—
Inception Date	18/11/2022
ISIN	IE0001APT67
BBG Ticker	UTGFPIID
BBG FIGI	BBG017CS5KZO
Min. Initial	500,000
Min. Subsequent	50,000

Management Fee	0.80%
Administrator	Citibank Europe PLC
Custodian	Citi Depository Ireland
Auditor	Ernst & Young

## Registered In

Ireland, Austria, Finland, France, Germany, Italy, Luxembourg, Netherlands, Spain, Switzerland, Singapore, UAE

## Portfolio Information



## Top Ten Holdings

Zomato Ltd	7.69%
PB Fintech Ltd	7.30%
Info Edge (India) Ltd	6.55%
IndiaMART InterMESH Ltd	5.94%
FSN E-Commerce Ventures Ltd	5.02%
Praj Industries Ltd	4.92%
MTAR Technologies Ltd	4.81%
Rategain Travel Technologies Ltd	4.64%
Nazara Technologies Ltd	4.48%
Affle India Ltd	4.48%

## Market Capitalization

Large Cap	11.53%
Mid Cap	34.93%
Small Cap	45.02%

■ UTI India Innovation EUR Instl Acc

This document does not constitute an Offer for share/units and is neither a recommendation nor statement of opinion or an advertisement. Past performance mentioned herein is/are not necessarily indicative of future performance. Investments in the Fund(s) are subject to risk, including possible loss of the principal amount invested. Investors must read the prospectus before making any investment decision. This document does not contain material information about the Fund, including important disclosures and risk factors associated with investment in the Fund.

## Important Legal Information

This report has been supplied solely for use by the person to whom it is made available. The Company makes no representation with regard to the completeness and accuracy of the data or information contained herein, and it accepts no responsibility and disclaims all liability for loss or damage whatsoever suffered or incurred by any other person resulting from the use of, or reliance upon, the data or information contained herein. Certain information in this document has been provided by third-party sources and, although believed to be reliable, it has not been independently verified and its accuracy or completeness cannot be guaranteed. The content of the statement are for illustration/ information & discussion purpose only without regard to the specific objectives, financial situation and particular needs of any specific person who may receive this statement, such person may wish to seek advice from a financial adviser before committing to invest in any of the Fund. If such person chooses not to do so, he should consider carefully whether the investment is suitable for him.

**Austria**  
Erste Bank der oesterreichischen Sparkassen AG (the "Paying Agent") having its registered office at OE 01980869, AM Belvedere 1, A-1100 Wien, Austria has been appointed as the paying agent and information agent in Austria in accordance with sec. 141 para 1 of the IFA 2011. Investors may seek further information as to the subscription and redemption procedure applicable to the Fund from the Paying Agent.

**Australia**  
This Factsheet is provided by 3PD Pty Limited ACN 642 919 926 (Australian Financial Services Licence No. 532567) for wholesale investors only. The information set out in this Factsheet is general in nature, does not contain any investment recommendations or advice and does not take into account the objectives, financial situation or needs of investors. Investing involves risk. Past performance is not an indicator of future performance. Before acting on any information, you should consider the appropriateness of it having regard to your particular objectives, financial situation and needs, and seek advice.

**Finland**  
The Funds are established under the laws of the Ireland and are marketed in Finland in accordance with Chapter XI of Directive 2009/65/EC as transposed into national legislation, including Section 128 of the Finnish Act on Mutual Funds (48/1999, as amended) unless otherwise stated herein.

**France**  
The Fund has been authorised for sale in France by the Autorité des Marchés Financiers. The centralising correspondent in France is CACEIS Bank, located at 1-3, place Valhubert, 75013 Paris. The Fund's Prospectus, key investor information document (KIID), most recent annual reports, half-yearly reports and Articles of Incorporation may be obtained from CACEIS Bank, Germany. Investors should note that, relative to the expectations of the Autorité des Marchés Financiers, this (UCITS) presents disproportionate communication on the consideration of non-financial criteria in its investment policy.

**Germany**  
The Bundesanstalt für Finanzdienstleistungsaufsicht (Federal Agency for Financial Services Supervision) has been notified pursuant to Sec. 132 Investmentgesetz (Investment Act) of the intention to publicly distribute Shares of the Fund in the Federal Republic of Germany. The legal documents can be obtained in German, free of charge, from the information agent. The Information Agent in Germany is GerFIS - German Fund Information Service UG (haftungsbeschränkt), Zum Eichhagen 4, 21382 Brietlingen, Germany.

**Singapore**  
The Fund is a recognised scheme under the Securities and Futures Act, Chapter 289 of Singapore ("SFA"). A copy of the Singapore Prospectus has been lodged with and registered by the Monetary Authority of Singapore ("MAS"). Investors from Singapore must read the Singapore prospectus and the product highlights sheet before making any investment decision. The MAS assumes no responsibility for the contents of the Singapore Prospectus. Registration of the Singapore Prospectus by the MAS does not imply that the SFA or any other legal or regulatory requirements have been complied with. The MAS has not, in any way, considered the investment merits of the Company. The distribution of this Singapore Prospectus and the offering or sale of the Shares in the Company in some jurisdictions may be restricted or prohibited. Persons who have possession of the Singapore Prospectus of the Fund must inform themselves about and observe such restrictions or prohibitions.

**Switzerland**  
The Company is authorized for public distribution in and from Switzerland by the Swiss Financial Market Supervisory Authority ("FINMA"). Investors from Switzerland should read the Consolidated Prospectus for use solely in Switzerland. The representative and paying agent in Switzerland is RBC Investor Services Bank S.A., Esch-sur-Alzette, Zurich Branch, Bleicherweg 7, CH-8027 Zurich, Switzerland (the "Representative"). In Switzerland, the funds prospectus, Key Investor Information Document (KIID), the articles of association, the annual and semi-annual reports may be obtained free of charge from the Representative. In respect of the units distributed in and from Switzerland, the places of performance and jurisdiction is the registered office of the Representative. This is an advertising document.

**Spain**  
The UTI Goldfinch Funds Plc, SICAV is duly registered in the CNMV official registry of foreign collective investment institutions as authorised to be marketed to the public in Spain with number 1668. In Spain, any investment must be made through the authorised distributors and on the basis of the information contained in the mandatory documentation that must be received from the authorised distributor of the SICAV prior to any subscription, or that may be obtained from the CNMV registries.

**United Arab Emirates**  
The Fund is registered with the Securities and Commodities Authority ("SCA") of UAE as a foreign investment fund. The fund can be offered and marketed by licenced distributor who has individually obtained approval from SCA to distribute this Fund. The information on the list of licenced distributor for this fund will be available from the investment manager of the Fund. UTI International (Singapore) Private Limited is regulated by the Dubai Financial Services Authority ("DFSA") to operate as a Representative Office. This document relates to a financial product which is not subject to any form of regulation or approval by the DFSA. The DFSA has no responsibility for reviewing or verifying any prospectus or other documents in connection with this financial product. Accordingly, the DFSA has not approved this document or any other associated documents nor taken any steps to verify the information set out in this document, and has no responsibility for it. The financial product to which this document relates may be illiquid and/or subject to restrictions on its resale. Prospective purchasers should conduct their own due diligence on the financial product. If you do not understand the contents of this document you should consult an authorised financial adviser.

**U.K**  
Any financial promotion contained herein, as defined by UK regulations, has been approved by UTI International Limited (FCA no:183361), a firm authorised and regulated by the Financial Conduct Authority ("FCA") U.K. The Fund mentioned herein has been recognised by the FCA pursuant to section 264 of the FSMA. Facilities Agent is UTI International Limited, 120 New Cavendish Street, London W1W 6XX, United Kingdom. Copies of the legal documents can be obtained in English, free of charge, from the Facilities Agent at 120 New Cavendish Street, London W1W 6XX, United Kingdom. The promotion of the Company in the United Kingdom can be carried out by persons authorized to carry on investment business in the United Kingdom under the FSMA and is not subject to the restrictions on promotion contained in section 238 of the FSMA. The FCA has not approved and takes no responsibility for the contents of the Prospectus or the UK Country Supplement or for any document referred to in them, nor for the financial soundness of the Fund or for the correctness of any statements made or expressed in the Prospectus or the UK Country Supplement or any document referred to in them.

**Italy**  
The Fund has been registered with the Commissione Nazionale per le Società e la Borsa (CONSOB) for the offer to Professional Investors (as defined in applicable CONSOB regulations) only. The promotion of the Fund and the distribution of its offering documents in Italy should be restricted to professional investors only and cannot be made by any means which may constitute a public offer or is addressed to or could result in the involvement of the public.

**Ireland**  
The Fund is an open-ended investment company with variable capital incorporated with limited liability in Ireland under the Companies Acts, 1963 to 2012 with registration number 516063 and established as an undertaking for collective investment in transferable securities pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011). The Fund is both authorised and supervised by the Central Bank. Authorisation of the Fund by the Central Bank shall not constitute a warranty as to the performance of the Fund and the Central Bank shall not be liable for the performance or default of the Fund. The authorisation of the Fund is not an endorsement or guarantee of the Fund by the Central Bank and the Central Bank is not responsible for the contents of the Prospectus of the Fund.

**Luxembourg**  
The Fund is established under the laws of Ireland and is marketed in Luxembourg in accordance with Chapter XI of Directive 2009/65/EC as transposed into national legislation, including Chapter 7 of the Luxembourg Law dated 17 December 2010 relating to undertakings for collective investment (as amended) unless otherwise stated herein. CACEIS BANK, LUXEMBOURG BRANCH having its registered office at 5, allée Scheffer, L-2520 Luxembourg, Grand-Duchy of Luxembourg, acting as a branch of CACEIS BANK, a public limited liability company (société anonyme) incorporated under the laws of France, has been appointed as paying agent and representative agent in Luxembourg for the Fund. Shareholders resident in Luxembourg may request the subscription and redemption of Shares and the payment of distributions in accordance with the provisions of the Prospectus directly from the Fund or via the Paying Agent. Luxembourg relevant taxation aspects as well as other additional information for investors in Luxembourg can be found in the Luxembourg Country Supplement, which forms part of, and should be read in conjunction with the Fund Prospectus.

**Netherlands**  
The Company registered with the Dutch Authority for Financial Markets (Autoriteit Financiële Markten). The register can be consulted through [www.afm.nl](http://www.afm.nl) registers. The Company's prospectus, key investor information document (KIID), most recent annual reports, half-yearly reports and Articles of Incorporation are available at [www.utifunds.com](http://www.utifunds.com).

**Other jurisdictions**  
The distribution of this document of the Fund or Prospectus of the Fund and the offering of Shares of the Fund may be restricted in certain jurisdictions. This document or the Prospectus of the Fund does not constitute an offer or solicitation in any jurisdiction in which such offer or solicitation is not authorised or the person receiving the offer or solicitation may not lawfully do so. It is the responsibility of any person in possession of this document or the Prospectus of the Fund and of any person wishing to apply for Shares of the Fund to inform himself of and to observe all applicable laws and regulations of the countries of his nationality, residence, ordinary residence or domicile.